SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
June 3, 2023
Date of Report (Date of earliest event reported)
Elicio Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-39990
|
11-3430072
|
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
451 D Street, 5th Floor
Boston, Massachusetts
|
02210
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (857)
209-0050
Not applicable
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common Stock, $0.01 par value per share
|
|
ELTX
|
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 8.01. Other Events
On June 3, 2023, Elicio Therapeutics, Inc. issued a press release
announcing positive interim data from the Phase 1 study of an
investigational therapeutic cancer immunotherapy, ELI-002, in
patients with high relapse risk pancreatic and colorectal cancer at
the American Society of Clinical Oncology (ASCO) annual meeting.
The press release contains statements intended as “forward-looking
statements” which are subject to the cautionary statements about
forward-looking statements set forth therein. The press release is
attached to this Current Report on Form 8-K as Exhibit 99.1 and
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No.
|
|
| |
|
|
|
Press Release of Elicio
Therapeutics, Inc., dated June 3, 2023.
|
| |
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL
document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
Date: June 5, 2023
|
Elicio Therapeutics, Inc.
|
|
|
|
| |
By:
|
/s/ Brian Piekos
|
| |
Name:
|
Brian Piekos
|
| |
Title:
|
Chief Financial Officer
|